About this program
IPH5201 is a blocking antibody targeting the CD39 immunosuppressive pathway.
CD39 is an extracellular enzyme that is expressed in the tumor microenvironment, on both tumor infiltrating cells and stromal cells in several cancer types. CD39 inhibits the immune system by degrading adenosine tripohsphate (ATP) into adenosine monophosphate (AMP), that is then further degraded into adenosine by CD73. By promoting the accumulation of immune-stimulating ATP, and preventing the production of immune-suppressive adenosine, the blockade of CD39 may stimulate anti-tumor activity.
Mechanism of action of IPH5201
In October 2018, Innate Pharma and AstraZeneca entered into a development collaboration and option agreement for further co-development and co-commercialization for IPH5201.
The Phase I clinical trial is evaluating IPH5201 in adult patients with advanced solid tumors. The purpose of the study, which is sponsored by AstraZeneca, is to evaluate IPH5201 as monotherapy and in combination with durvalumab (anti-PD-L1) with or without oleclumab (anti-CD73 monoclonal antibody).
The multicenter, open-label, dose-escalation Phase I study will evaluate the safety, tolerability, antitumor activity, pharmacokinetics (PK), pharmacodynamics (PD) and immunogenicity of IPH5201 alone, or in combination with durvalumab, with or without oleclumab. More information on the Phase I clinical trial can be found at
Ivan Perrot et al, 2019. Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies Cell Reports Bastid et al, 2015. Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity Cancer Immunol Res. Bastid et al, 2013. CD39 is a promising therapeutic target in oncology Oncogene